Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Illumina, Inc. — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6, while Illumina, Inc. trades at $191.95 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | ILMN | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $205.10 |
52-Week Low | $24.83 | $91.00 |
Market Cap | — | $29.12B |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
